Cipla’s Managing Director and Global CEO, Umang Vohra, has clarified that the recent US government directive mandating price reductions for prescription medicines within 30 days will have no significant impact on Indian generic drug manufacturers. The Executive Order’s implementation details, particularly around Most Favored Nation (MFN) clauses, remain unclear.

Currently, India imposes approximately 10% import duty on American pharmaceuticals, whereas Indian drugs entering the US market face no tariffs. The Trump administration is reportedly considering tariffs on drug imports to the US, but Indian pharma firms have been exempted from reciprocal tariffs in recognition of their crucial role in providing affordable medicines globally.

Cipla underscores that the Indian pharmaceutical industry’s position remains stable despite evolving US policies, reinforcing its continued commitment to global healthcare.